Overview

Antiproteinuric Effect of Valsartan and Lisinopril

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Title: Antiproteinuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), double blind, parallel group, controlled trial, 5 months follow-up. Objective: To evaluate the antiproteinuric effect of high doses of valsartan vs combo treatment in no-diabetic and diabetic patients. Hypothesis: Combo treatment reduces microalbuminuria, proteinuria and the albumin/creatinin ratio more than monotherapies. Design: Multicentric, randomized, double blind, parallel group, active controlled. Dose / regimen Valsartan 320 vs Lisinopril 40 vs Valsartan/lisinopril 160/20
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Lisinopril
Valsartan